K
Kinoxis Therapeutics
A biotechnology startup developing new therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric…
About Kinoxis Therapeutics
Kinoxis Therapeutics is a pioneering biopharmaceutical company based in Melbourne, Australia, specializing in the development of therapeutic compounds aimed at enhancing social functioning by targeting specific pathways in the brain. The company primarily focuses on the oxytocin receptor, utilizing selective partial agonism and positive allosteric modulation to restore normal social behavior. Kinoxis serves patients suffering from social dysfunction and substance abuse disorders, operating within the behavioral neuroscience and psychiatric treatment markets. The business model revolves around extensive research and development, backed by significant funding from venture funds like Uniseed and grants from institutions such as the US National Institutes of Health National Institute on Drug Abuse. Revenue is generated through partnerships, licensing agreements, and the commercialization of its therapeutic compounds.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Melbourne, Australia
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 74.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Addiction, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Dec 2024 | $1.6M | — | Undisclosed | ↗ |
| SERIES B✓Equity / VC | Aug 2024 | $9.4M | $38M | Lis Boyce · Stoic Venture Capital · Avicella Capital · University of Sydney | ↗ |
Growth signals
Latest recorded traffic for Kinoxis Therapeutics is 1.3K monthly website visits, up 160% over the last three months. Kinoxis Therapeutics's team grew 5.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Stoic Venture Capital
National Institutes of Health
Innovation Connections
Series A6 investors entered at this stage
Uniseed Ventures
Brisbane Angels
Lis Boyce- ACAvicella Capital
University of Sydney
UniSuper
Other known investors1 additional known investor
Angel Loop
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kinoxis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kinoxis Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.